Strumento inattivo

Altre lingue Zalicus Inc Nasdaq

Azioni

US98887C1053

Prezzo di chiusura Nasdaq Altri mercati azionari
- ^USD	-

2016	Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016
2015	Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	09/10/18
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	31/01/18
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	19/01/18
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.	18/01/18
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.	11/12/17
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	19/09/16
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index	05/08/16
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index	03/08/16
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations	25/07/16
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy	25/07/16
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination	01/07/16
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..	30/06/16
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.	14/06/16
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes	09/05/16
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	29/03/16
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	15/03/16
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)	09/02/16
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015	16/11/15
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	16/11/15
EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer	10/11/15

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Zalicus Inc Nasdaq

Azioni

US98887C1053

Altre lingue

Filtri